Pancreatic Cancer Trial, Recruiting NCT05727020 Sponsor: Imperial College London Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT05727020
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People of any gender aged 18 or older
  • For the VAPOR 1 part of the trial: people who have been diagnosed with pancreatic cancer (confirmed by tissue testing), people who have recently developed diabetes or have chronic pancreatitis, or people with general digestive symptoms but a normal-looking pancreas on scans
  • For the VAPOR Bioresource part of the trial: people who are scheduled to have pancreatic surgery for either confirmed pancreatic cancer, or non-cancerous pancreatic conditions such as certain types of cysts or chronic pancreatitis
  • People scheduled for surgery where pancreatic cancer is suspected but not yet confirmed by tissue testing may also be considered, provided cancer is confirmed in the removed tissue after surgery (confirm with trial site)

Who may not be able to join:

  • People who have already received chemotherapy, radiation therapy, or surgery for their pancreatic cancer
  • People who have had another cancer diagnosed within the past five years
  • People who have previously had surgery on the upper part of the digestive system
  • People who are unable to provide a breath sample
  • People who are pregnant
  • People who are unable to give written informed consent
  • For the VAPOR 1 part: people who currently have an active infection, or who have taken immunosuppressive medications or antibiotics in the past eight weeks
  • For the VAPOR Bioresource part: people who have taken immunosuppressive medications in the past eight weeks

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Professor George B Hanna, PhD, FRCS, Imperial College London

Phone: +44 (0)20 7594 3653

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 December 2022
Est. completion
1 August 2028

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Levels of VOCs present in breath of subjects with PDAC and controls

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov